Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.34 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.34 |
| ▸ | KDM5A | P29375 | 6/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 6/20 | 0.44 |
| ▸ | KDM5B | Q9UGL1 | 6/20 | 0.44 |
| ▸ | HTR7 | P34969 | 2/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 3/20 | 0.34 |
| ▸ | KDM4A | O75164 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12433863 | 0.92 | HTR7 (0.45) | KDM5AKDM4CKDM5BHTR7NR3C2 | |
| Succinic Acid SCHEMBL2209062 | 0.91 | HTR2B (0.38) | KDM5AKDM4CKDM5BHTR7NR3C2 | |
| Succinic Acid SCHEMBL2209289 | 0.90 | KDM5A (0.39) | KDM5AKDM4CKDM5BHTR7NR3C2 | |
| Succinic Acid SCHEMBL2205175 | 0.89 | ASIC3 (0.39) | HTR2CHTR2BMAPK14FFAR1PARP10 | |
| Succinic Acid SCHEMBL2208833 | 0.87 | MAPK1 (0.40) | KDM5AKDM4CKDM5BFFAR1PDE4B | |
| Succinic Acid SCHEMBL2211440 | 0.86 | CYP11B2 (0.35) | KDM5AKDM4CKDM5BHTR2CHTR2B | |
| Succinic Acid SCHEMBL2207455 | 0.86 | HTR2A (0.37) | KDM5AKDM4CKDM5BNR3C2HTR2C | |
| Succinic Acid SCHEMBL2208252 | 0.84 | HTR2C (0.37) | KDM5AKDM4CKDM5BHTR2CHTR2B | |
| Succinic Acid SCHEMBL2206649 | 0.83 | HTR2A (0.35) | KDM5AKDM4CKDM5BHTR2CHTR2B | |
| Succinic Acid SCHEMBL2205633 | 0.83 | HTR2A (0.34) | KDM5AKDM4CKDM5BNR3C2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1924578-B1 | 6-N-LINKED HETEROCYCLE-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | LILLY CO ELI (US) | 2013-11-06 | — | — | EP | disclosed |
| US-7981882-B2 | e.g. 7-Chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine; antidepressant, anxiolytic agent; obesity, obsessive/compulsive disorder | ELI LILLY AND COMPANY (US) | 2011-07-19 | — | — | US | disclosed |
| US-20080214520-A1 | 6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists | ELI LILLY AND COMPANY | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214520-A1 | 6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists | HTR2C, HTR3B, HTR1A | HTR2C 1/4885HTR2A 5/4885KDM5A 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.